The U.S. Food and Drug Administration (FDA) has authorized the marketing of six nicotine pouch products through the premarket tobacco product application (PMTA) pathway, marking the first decisions issued under a pilot program launched to streamline nicotine pouch reviews. The program enabled faster evaluations through process changes such as real-time communication with applicants, while maintaining scientific review standards.

The authorized products, manufactured by Helix Innovations LLC and sold under the on! PLUS brand, include mint, tobacco, and wintergreen flavors at 6 mg and 9 mg nicotine strengths. The FDA determined that these products meet the public health standard set by the Family Smoking Prevention and Tobacco Control Act, finding they contain lower levels of harmful constituents compared with other oral tobacco products and may provide a net benefit for adults who switch from cigarettes or other smokeless tobacco.

The authorizations include strict marketing restrictions to limit youth exposure, requirements for child-resistant packaging, and ongoing reporting obligations to monitor youth prevention measures. The FDA emphasized that the products are not risk-free or “FDA approved,” and that the authorization applies only to these six specific products.

Consumer News Region
Consumer News Tags
U.S. Food and Drug Administration (FDA); Nicotine pouch; Premarket tobacco product application (PMTA)